ClinicalTrials.gg
RecruitingNCT06934564Updated May 8, 2026

De-Implementation of Low-value Testing in Patients Undergoing Low-Risk Surgery

An interventional study of Active de-Implementation in Breast Lumpectomy, Laparoscopic Cholecystectomy and Inguinal Hernia Repair, sponsored by University of Michigan. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by University of Michigan · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 77 studies in Hernia, Inguinal with a site in United States — 9 open to participants now, 20 under way, none of them phase 3. Hernia, Inguinal · United States.

Planned enrollment
57th of 60
16 · median 100
Started
2025
with 2 others
No phase
36 of 77
7 open now
Primary completion
2026-12
later than 9 of 19 live
Registered
71st of 77
by date

Among the 77 studies in Hernia, Inguinal with a site in United States, this one is the 57th largest by planned enrollment of the 60 interventional ones that give a count, is one of 3 that started in 2025, is one of 36 with no phase, reaches primary completion later than 9 of the 19 other live ones, and was the 71st registered.

Hernia, Inguinal

545 studies on the registry are indexed under Hernia, Inguinal; 91 are open to participants now.

Browse Hernia, Inguinal studies →

Open to participants now

9 of the 77 studies in Hernia, Inguinal with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 54 Hernia, Inguinal studies recruiting now, 30 (56%) set no upper age limit and 16 (30%) stop at 75 or younger; 16 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Hernia, Inguinal with a site in United States, or all of them as a file.
02

Study summary

This trial aims to evaluate the effectiveness of a multi-level, multi-component de-implementation strategy to reduce unnecessary preoperative testing. Sixteen Michigan Value Collaborative (MVC)/Michigan Surgical Quality Collaborative (MSQC) sites in Michigan will implement several tools that have been proven to reduce unnecessary testing at a single site, including clinician education, a decision aid, audit and feedback on performance, and a pay-for-performance incentive. The researchers believe that, through the use of these strategies, there will be a significant reduction in unnecessary preoperative testing during the intervention.

03

Conditions studied

  • Breast Lumpectomy
  • Laparoscopic Cholecystectomy
  • Inguinal Hernia Repair

Browse trials for

Keywords

  • Preoperative testing
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Site

Inclusion criteria

Inclusion Criteria:

  • Over 30% of testing rates on at least one of the three index procedures (breast lumpectomy, laparoscopic cholecystectomy, and inguinal hernia repair)

Exclusion criteria

Exclusion Criteria:

  • none

Surgical participants must be over 18 years old.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    Wave 1

    Each wave will include usual care, preparation (8 weeks before intervention), active de-implementation interventions, and sustainment phases. Intervention is Year 1 Quarter 2

    Behavioral: Active de-Implementation

  • Experimental
    Wave 2

    Each wave will include usual care, preparation (8 weeks before intervention), active de-implementation interventions, and sustainment phases. Intervention is Year 1 Quarter 3

    Behavioral: Active de-Implementation

  • Experimental
    Wave 3

    Each wave will include usual care, preparation (8 weeks before intervention), active de-implementation interventions, and sustainment phases. Intervention is Year 1 Quarter 4

    Behavioral: Active de-Implementation

  • Experimental
    Wave 4

    Each wave will include usual care, preparation (8 weeks before intervention), active de-implementation interventions, and sustainment phases. Intervention is Year 2 Quarter 1

    Behavioral: Active de-Implementation

  • Experimental
    Wave 5

    Each wave will include usual care, preparation (8 weeks before intervention), active de-implementation interventions, and sustainment phases. Intervention is Year 2 Quarter 2

    Behavioral: Active de-Implementation

  • Experimental
    Wave 6

    Each wave will include usual care, preparation (8 weeks before intervention), active de-implementation interventions, and sustainment phases. Intervention is Year 2 Quarter 3

    Behavioral: Active de-Implementation

Interventions

  • BehavioralActive de-Implementation

    During active de-implementation (3 months), the local team will distribute the strategy components (i.e., clinician education, decision support, evaluation, consensus building around perioperative testing pathways, facility-specific feedback, and a pay-for-performance incentive) at the local site.

06

What researchers measure

Primary outcomes

  1. Number of tests within 30 days of surgery not associated with an emergency department visit

    Only tests relating to three index procedures; breast lumpectomy, laparoscopic cholecystectomy, and inguinal hernia repair Data collected using MVC/MSQC database

    Time frame: Within 30 days of surgery

Secondary outcomes

  1. Number of unnecessary preoperative testing before low-risk surgery at MVC/MSQC sites not participating in the trial

    Example related operations: laparoscopic hysterectomy, knee arthroscopy

    Time frame: Up to year 2, quarter 4

  2. 30-day episode-based spending

    Using the MVC claims data for total spending amounts

    Time frame: Up to Year 2, Quarter 2

  3. Number of unnecessary preoperative testing before low-risk surgery at trial sites

    Example related operations: laparoscopic hysterectomy, knee arthroscopy

    Time frame: Up to year 2, quarter 4

  4. Number of intraoperative complications

    Examples: myocardial infarction, stroke

    Time frame: Up to year 2, quarter 4

  5. Number of same-day case cancellations

    Time frame: Up to year 2, quarter 4

07

Study locations

1 of 1 sites recruiting
  • University of Michigan and other Michigan Surgical Quality Collaborative sites
    Ann Arbor, Michigan 48109, United States
    Recruiting
    • Dana Greene Jr., MPH · Contactgreenejr@med.umich.edu · (313)-670-0408
    • Lesly Dossett, MD, MPH · Principal investigator
    • Hari Nathan, PhD · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Dec 2026, 20 months after the start.

Of 179 non-industry interventional studies with no phase under Hernia, Inguinal, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 35. This study's planned 20 months is close to that.

Counting every sponsor, half of 188 studies reached it within 19 months; a quarter within 9 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2025
First posted
Apr 18, 2025
StartActual
Apr 1, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06934564
Collaborators
Agency for Healthcare Research and Quality (AHRQ), Blue Cross Blue Shield of Michigan Foundation
Responsible party
Hari Nathan (Associate Professor of Surgery, University of Michigan) — Principal investigator
First posted
Apr 18, 2025
Start date
Apr 1, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
May 8, 2026

Study contacts

Dana Greene Jr., MPH
Contact
greenejr@med.umich.edu
(313)-670-0408
Valerie Gavrila
Contact
gavrilva@umich.edu
734-232-9961
Lesly Dossett, MD, MPH
principal investigator · University of Michigan
Hari Nathan, PhD
principal investigator · University of Michigan

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion